gip glp 1 glucagon agonists Science Behind and Receptor for Obesity Research | News & Announcements Triple GLP-1 / GIP /

Introduction Our study has two objectives: (1) to evaluate the incidence and severity of food retention observed during esophagogastroduodenoscopies (EGDs) in patients with and without history of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and (2) to create a grading scale to standardize the language regarding food retention

Nevertheless, the overall drug exposure was not considered clinically significant

Please note: The Microdosing Program is offered only at a fixed, low starting dose and does not increase over time

GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways

Most patients in both groups had no significant gastric retention at the time of EGD